Bio Job Blog : Bio Jobs : Biotechnology Jobs : Biopharmaceutical Jobs : Bioscience, Biotech Jobs : Bio Job Blog : Biocareer : Bio-Business Training, Biotechnology Training : Jobs in Biology : Internships in Biology : Internships in Biotechnology

Five years ago Amgen was the world’s largest biotechnology and was, by many accounts, the darling of Wall Street. But, today, there is little mention of the once formidable biotechnology company that many startups attempted to emulate. Like other companies, Amgen ran into pipeline problems, medical issues with existing blockbuster drugs (remember the whole hematocrit brouhaha over Epogen and Aranesp its flagship anemia products), lower drug sales and ultimately the perception that the company had lost its innovative edge. However, it now appears that Amgen is making something of a comeback and may have been quietly preparing itself for its  “rebirth” over the past few years.

According to an article in today’s NY Times, Amgen agreed to purchase BioVex, a closely held oncology company for $425 million and as much as $575 million in milestone payments. BioVex’s lead product, an experimental cancer vaccine Oncovex, is in late stage clinical development. It was developed to treat metastatic melanoma. Oncovex is also being evaluated for head and neck cancer.  Over the past five years, Amgen has acquired seven companies (with an average deal value of about $264 million) in oncology and other therapeutic areas indicating a willingness to create new drugs to treat diseases rather than symptoms commonly associated with them.

In other news, the company announced that it was raising it price for some of its largest selling drugs including Aranesp, Neupogen and Neulasta. Another sign that the once mighty company may be trying to get back into the game and compete with archrival Genentech (now a subsidiary of Roche) for the title of the world’s largest biotechnology company.

Until next time...

Good Luck and Good Job Hunting!!!!!!.

• Email This
• Print
• Comments
• Trackbacks
• Share Link

The fiscal year at most life sciences companies is drawing to a close, new budgets are being crafted and the holiday season is almost upon us. In years past, this time of year typically meant that it was bonus time for most pharma workers. Sadly, over the past three years bonus time has been replaced by layoff time. And, unfortunately the upcoming holiday season may not be joyous for many Pfizer and Roche employees.

Yesterday, Pfizer indicated that it may lay off up to 11,700 more employees than the 19,500 it had announced in connection with the buyout last year of Wyeth Pharmaceuticals. While Pfizer confirmed that it would be reducing its worldwide work force by more than the originally expected 19,500 the exact number remains a mystery. However, a quarterly report filed Friday with the U.S. Securities and Exchange Commission stated that Pfizer has estimated termination costs for 46,600 employees, while only 33,400 workers had actually been laid off as of Oct. 3. This appears to suggest that the company plans to reduce its work force by 11,700 more than originally announced, given that Pfizer is only 1,500 positions away from fulfilling its job-elimination pledge related to the Wyeth merger.

The additional job cuts—if they are realized—would amount to about 10 percent of Pfizer’s worldwide work force. If a reduction of that magnitude were applied to Pfizer drug-research sites in Groton and New London, which currently employ nearly 5,000 workers, about 500 jobs would be lost. The company in January 2009 announced that cuts would total 15 percent of the combined Pfizer and Wyeth work force. At the time, the combined work force numbered about 130,000; the latest official figure places that number at 111,500.

In other news, Roche today announced plans to cut 4,800 jobs, or 6 percent of its worldwide workforce of 82,000. Today’s announcement confirms the news leak three months ago (reported by the Pharmalot Blog) which suggested that job cuts would be likely during the fall.

According to today’s press release, technical operations activities will be reorganized in California, Mannheim, Germany and various other sites, resulting in the elimination of 750 jobs. The company also intends to sell sites in Florence, South Carolina and Boulder, Colorado; shedding an additional 600 jobs. About 1,200 jobs will be cut in the North American commercial operations, mainly in Roche’s primary-care business, while 700 positions will be lost in commercial operations in Europe.

R&D will also be affected. The company will discontinue activities in research and early development in RNA interference in Kulmbach, Germany, Nutley, New Jersey, and Madison, Wisconsin. Also, there are plans to reorganize other operations at these sites which will eliminate another 600 jobs.

Until next time...

Good Luck and Good Job Hunting (are there any left?)!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Vincent Racaniello, virologist extraordinaire and a BioCrowd co-founder is slated to appear on ABC World News this evening to discuss Rebecca Sloot’s new book entitled The Immortal Life of Henrietta Lacks. The book details the life of little-known Henrietta Lack whose cancerous cervical cells (subsequently called HeLa cells by the scientists who managed to cultivate and immortalize them in the laboratory), revolutionized the field of virology and changed the way viral vaccines are manufactured.

Rebecca Skloot, the author, is an award-winning science writer, and a contributing editor at Popular Science magazine; she's worked as a correspondent for the NPR show RadioLab, and PBS Nova ScienceNOW. Her writing appears in The New York Times Magazine, O: The Oprah Magazine, Discover and others. The “Immortal Life of Henrietta Lack” is her first book.

So, why is Vincent being featured on tonight’s newscast about the HeLa book? For those of you who don’t know, Vincent has spent almost 30 years unraveling the molecular mechanisms by which the polio virus causes disease. And, as many of you may know, HeLa cells are the cell line of choice to cultivate polio virus in the laboratory. In addition to cloning the polio virus receptor in HeLa cells, members of Vincent’s laboratory have elucidated the genes and their proteins responsible for the neurotrophic effects of the virus that can lead to paralysis from polio infections. Further, for those of you who may not know, Vincent, while a postdoctoral fellow in David Baltimore's laboratory, was the first to demonstrate that transfection of HeLa cells with cDNA made from polio virus genomic RNA (using the newly discovered HIV reverse transcriptase enzyme that resulted in Baltimore winning the 1975 Nobel Prize in Physiology or Medicine) yielded infectious polio virions.

While Vincent’s findings greatly aided research to elucidate the underlying pathogenic mechanisms of the polio virus, it transformed and revolutionized the entire field of RNA virology. Prior to Vincent’s discovery, it was impossible to study the molecular biology of RNA viruses using recombinant methods because unlike DNA, there are no known RNA restriction enzymes. The ability to transcribe viral RNA into cDNA molecules that yield infection RNA viral particles permitted researchers to dissect RNA virus genomes (using recombinant DNA technology) to determine contribution of individual genes to viral pathogenesis.

Vincent, one of only a handful of virus pioneers, is now applying his considerable pioneering talents to social media because he believes that Web 2.0 tools like blogs, podcasts, videos and social networking sites can be successfully used for science education and improving the public understanding of the life sciences.

Until next time...

Good Luck and Good Viewing (ABC World News Tonight)!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Over the past few years, a number of search engines designed for the life sciences have appeared. I thought it might be informative for BioJobBlog readers to list some of the more popular ones and how they are used. I want to warn you in advance that this is not a comprehensive list. That said, if I’ve inadvertently omitted your favorite search engine, please feel free contact me or simply list it in the comments section for this post.

Scirus

Searches over 450 million scientific items, and allows researchers to search for not only journal content but also scientists’ homepages, courseware, pre-print server material, patents and institutional repository and website information. This site is owned and managed by Elsevier.

Novoseek

Search engine for biomedical literature in medline, grants and full text publications that will help you to: 1) retrieve meaningful documents related to your search, 2) narrow your search to find results in the relevant scientific journals and 3) identify the most relevant biomedical concepts for your query.

Mednar

Mednar is a free, publicly available medical research run by Deep Web Technologies.

Valdo 

A search engine that caters to all branches of life sciences. VADLO allows users to search within five categories: Protocols, Online Tools, Seminars, Databases and Software.

Life Sciences Search Engine

A customized search engine developed for the benefit of researchers in life science.

ScienceHack

BioPages

Australian web portal and life sciences search engine.

Science Bucket

Specialized search engine that filters biology sites.

GoPubMed

Knowledge-based search engine for biomedical texts. It allows users to identify experts in the biomedical field.

Until next time...

Good Luck and Good Searching!!!!!!!!

• Email This
• Print
• Comments (3)
• Trackbacks
• Share Link

In the February issue of Genetic Engineering and Biotechnology News, J. Leslie Glick a former CEO of Genex and veteran of the biotechnology industry put forward a novel solution to financial crisis that is currently gripping the life sciences industry and the rest of the US economy. Dr. Glick proposed that the US government ought to consider injecting taxpayer monies into venture capital firms (VC) which, he believes, would foster creation of new companies, create more jobs, stimulate the ailing economy and also provide the government with an outstanding return on its investment.

According to Dr. Glick, “historical results reported by the National Venture Capital Association for the 20 year period ending December 31, 2007, show an annualized return of 16.7% to investors in some 1,860 U.S. venture capital and private equity partnerships. If the U.S. government had made annual investments of $10 billion in VC firms throughout the U.S. during that 20year period, the $200 billion total investment would have yielded a total return of almost $1.5 trillion.” Further, he asserts that according to the  International Trade Administration of the Department of Commerce, from 1970 to 2000, U.S. VC firms invested over $270 billion in more than 16,000 companies. In 2000, the surviving VC-backed companies employed 7.6 million people, representing 5.9% of all U.S. jobs, and generated sales of $1.3 trillion, accounting for 13.1% of the U.S. GDP.

This financial upside sound enticing but who is going to keep track of the money and keep an eye on how and what the VCs are investing in? Dr. Glick proposes creation of a non-partisan funding mechanism, possibly overseen by an independent panel of business people that would disburse $10 to $25 billion annually of taxpayer’s dollars to vetted and certified VC firms. Because of its investment, the US government would become a limited partner in these firms and could direct them to invest in technologies that would help to reduce health care costs, develop energy alternatives or improve food production capacity. While this proposal is unprecedented and controversial, we are living in extremely uncertain financial times that may necessitate innovative and out-of-the-box solutions to restore normalcy to the US economy. That said, all proposals—no mater how unconventional or outrageous—ought to be carefully evaluated and vetted to determine whether or not they have merit to help overcome our deepening recession.

Kudos to Dr. Glick!

Until next time,

Good Luck and Good Investing!!!!!!

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

Today is a sad day in the pharmaceutical and biotechnology blogging world. Pharmalot, a two year old, pioneering blog created by the intrepid Ed Silverman and the Star Ledger News has decided to call it quits. Unfortunately, the Star Ledger is in dire financial straits and it could no longer provide Ed with the support he needed to continue to run the Pharmalot blog. Please read Ed’s last blog post for the full story.

Pharmalot was a well crafted and informative blog. I frequently (more times then I care to admit) used Pharmalot as source material for many of my posts at BioJobBlog. I am not sure how I will fill the void left by Pharmalot’s untimely  demise!

I first met Ed about 8 years ago when he did a story about a biopharmaceutical company that I founded (along with Abe Abuchowski) called Prolong Pharmaceuticals.  His coverage was outstanding and I am pleased to report that Prolong is still in business today. Ed and I reconnected a little over a year ago at a panel discussion about scientific integrity and journalism. Ed shared the podium with the WSJ Health Blog, the New York Times, Advanstar Publications and several well known authors who write about pharma and biotech. I was truly impressed with his understanding of the pharmaceutical industry (he is a journalist not a scientist) and his commitment to telling people the truth regardless of the consequences. I took his message to heart and have attempted to apply the same philosophy to my posts at BioJobBlog.

I want to personally thank Ed for his unwavering commitment to journalistic integrity and his help in ferreting out the truth. I wish him the best for whatever the future may hold for him—he will be sorely missed.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!
 

• Email This
• Print
• Comments
• Trackbacks
• Share Link

This month Kevin has reviewed an eclectic bunch of websites. Continuing with his “down under” theme from last month, Kevin offers the Australian National Herbarium and the Darwin Correspondience Project websites (okay so Darwin was English but he did visit Australia!). The Darwin site complements an interesting site called the Origin of Life Prize (check it out).  

Another Australian website called the Sea Snake Homepage covers everything you ever wanted to know about sea snakes (and then some) but as Kevin put it may not be for everyone. There is a technical site called Microscope-Microscope.org which has some terse but valuable information on well—microscopes.

My personal favorite is the Biomedia Associates Educational Biology site. Although it is a commercial site, it is an education website and offers some valuable resources for biology teachers and students.

Until next time…

Good Luck and Good Surfing!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link